This HTML5 document contains 163 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n10http://dx.doi.org/10.1136/
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34092469
rdf:type
wikibase:Item
schema:description
artigo científico vetenskaplig artikel 2014年論文 artículo científico publicado en 2014 2014 թվականի ապրիլին հրատարակված գիտական հոդված wetenschappelijk artikel 2014年の論文 مقالة علمية articolo scientifico tieteellinen artikkeli videnskabelig artikel (udgivet 2014) 2014 nî lūn-bûn artikull shkencor 2014年论文 мақолаи илмӣ article científic 2014年论文 научная статья scientific article artykuł naukowy vědecký článek مقالهٔ علمی 2014年論文 מאמר מדעי artículu científicu espublizáu en 2014 tudományos cikk article scientifique (publié 2014) научни чланак bài báo khoa học naučni članak 2014年论文 article scientific επιστημονικό άρθρο سائنسی مضمون наукова стаття, опублікована у квітні 2014 artikulong pang-agham articol științific 2014年论文 vedecký článok ২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ mokslinis straipsnis научни чланак scienca artikolo wissenschaftlicher Artikel 2014年論文 vitenskapelig artikkel บทความทางวิทยาศาสตร์ 2014年論文 artigo científico (publicado na 2014) bilimsel makale 2014年论文 мақолаи илмӣ artigo científico (publicado na 2014) სამეცნიერო სტატია teaduslik artikkel 2014년 논문 2014年论文 2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած 2014年論文 научна статия vitskapeleg artikkel
p:P577
wds:Q34092469-764E8F5A-A4D9-48F7-8F3B-BABFFC572A2B
wdt:P577
2014-04-03T00:00:00Z
p:P407
wds:Q34092469-FD41B9B8-E7DC-45D2-99A8-BEABD09F9E7C
wdt:P407
wd:Q1860
p:P2860
wds:Q34092469-C5CA5D19-3C70-4256-AF53-5BCD1B15F1ED wds:Q34092469-98D94642-CE34-4654-BB59-BAA0D97D66FC wds:Q34092469-7F822807-682E-4919-8A90-E032594AAFEE wds:Q34092469-8A2351A0-1607-440C-B9CB-580780C559AA wds:Q34092469-1F654BE0-8533-4644-AD14-FDE1090D3203 wds:Q34092469-270BD60F-BD78-4C69-BBE3-EC98868EF7BB wds:Q34092469-2C8577D8-6D1F-4015-9196-58B390D7DD2C wds:Q34092469-01AA5110-0C9A-4DDF-991A-BC4F5F5637CD wds:Q34092469-0CDB39F0-84F7-4B4C-84EB-21EB0A754F6D wds:Q34092469-1AAA02F5-1E4A-4A6C-84F4-CC85556EDBD0 wds:Q34092469-FD1FA461-60F1-43AC-88F3-F9B008E1CF26 wds:Q34092469-DB8D2F02-A396-4AE5-B983-35224EDC5D96 wds:Q34092469-5960223D-B20E-4AE0-AA68-94A30B7E5963 wds:Q34092469-37467ECD-BAAC-4B52-A38F-599684619B0A wds:Q34092469-423F8D0C-F879-4D46-8258-DA1DA227AE8D wds:Q34092469-45513883-12A2-4B46-A8B7-A0E2819E38A9 wds:Q34092469-CD63FE55-7D2C-4A4B-BBF3-EAECDC9620E9 wds:Q34092469-D4E513B7-CFB4-40F8-9810-86149CE6309C wds:Q34092469-D750F98B-25A8-4DB0-B767-084954E9C89B wds:Q34092469-D7DA78EF-BF5F-49B3-98CA-BD829F151CAC wds:Q34092469-9DFE7752-A7B3-4A41-8E57-C4D3FD9EF273
wdt:P2860
wd:Q21093257 wd:Q36274467 wd:Q27860872 wd:Q24817087 wd:Q57169361 wd:Q37980421 wd:Q68094829 wd:Q69049138 wd:Q47643186 wd:Q38176549 wd:Q83431012 wd:Q26859134 wd:Q29396936 wd:Q55049410 wd:Q34092311 wd:Q73128367 wd:Q34566660 wd:Q56879288 wd:Q40850225 wd:Q80201780 wd:Q26778425
p:P2093
wds:Q34092469-74CAF9D1-234F-48D0-8443-EE3A72557BD7 wds:Q34092469-77AD447F-E13C-4EE5-AC01-52C5B3C70818 wds:Q34092469-3F5E603D-D71C-4730-AC4C-D7B1CDADAD38 wds:Q34092469-F0E4303F-28EA-4C27-8D1A-FD4F68D31F3E
wdt:P2093
Shihong Sheng Benjamin Hsu Michael E Weinblatt Yanli Zhuang
rdfs:label
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
skos:prefLabel
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
schema:name
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
p:P50
wds:Q34092469-6DF91712-C329-42C3-9905-4C978CAFAFBD
wdt:P50
wd:Q66753681
p:P1476
wds:Q34092469-559C5AAF-DA26-43BA-AADE-05ED30DA123B
wdt:P1476
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
p:P304
wds:Q34092469-AA8F9249-20C7-41EE-B4E2-B1156E797633
wdt:P304
1616-1625
p:P31
wds:Q34092469-1B1D872C-DE39-46C1-ACF4-12ABFB6C6035
wdt:P31
wd:Q13442814
p:P921
wds:Q34092469-6707CB6B-A364-41BE-A889-369042CA5381 wds:Q34092469-7E46809A-3591-467F-9A1D-EF3FBDC3A6D7 wds:Q34092469-93BAEC15-E616-428E-B4AD-D93A25E8D10D wds:Q34092469-96C8D80F-FA6E-477A-AB25-5D05BF2F0131 wds:Q34092469-98e14924-e7a1-4acb-a28b-98648ed8658d wds:Q34092469-9BCD4CBD-2047-4AB5-906A-51BBF4532999
wdt:P921
wd:Q422248 wd:Q422232 wd:Q79460 wd:Q194908 wd:Q187255 wd:Q181600
p:P698
wds:Q34092469-E8833E2C-8E27-4CEA-BB4A-D67C4C9F4611
wdtn:P698
n11:24699939
wdt:P698
24699939
p:P1433
wds:Q34092469-5C5D9837-7585-45B1-B9CB-822EE5BB0B91
wdt:P1433
wd:Q4767876
p:P433
wds:Q34092469-731DA59B-8B93-452C-A07E-82744EACF048
p:P478
wds:Q34092469-A9B36854-D0D1-4B30-A8A3-FC04B5E0819B
wdt:P433
9
wdt:P478
73
p:P356
wds:Q34092469-79AADDE6-8A93-4F87-A87F-D990A980F207
wdtn:P356
n10:ANNRHEUMDIS-2013-205137
wdt:P356
10.1136/ANNRHEUMDIS-2013-205137
p:P8608
wds:Q34092469-F7C804A1-170E-452F-8ADE-D26A7B67BF54
wdt:P8608
release_vm2u6jlzefgzbdmob35w2yxa2u
p:P5875
wds:Q34092469-9235B126-BDEF-45A5-A5C8-7B21D1CCCF05
wdt:P5875
261373640
p:P932
wds:Q34092469-72611EA4-5B63-43EC-B09B-54EB8E5C093C
wdt:P932
4145446